CLDN18.2-targeting ADC for GEC clears phase III trial

12 Nov 2026
Audrey Abella
Audrey AbellaEditor; MIMS
Audrey Abella
Audrey Abella Editor; MIMS
CLDN18.2-targeting antibody–drug conjugate for gastroesophageal carcinoma clears phase III trial.CLDN18.2-targeting antibody–drug conjugate for gastroesophageal carcinoma clears phase III trial.

In the CLARITY-Gastric01 trial, the claudin 18.2 (CLDN18.2)-targeting antibody–drug conjugate (ADC) sonesitatug vedotin (Sone-Ve) doubled the median overall survival (OS) in individuals with previously treated advanced or metastatic CLDN18.2+ gastroesophageal carcinoma (GEC).

In the third- or later-line (3L+) population, the co-primary endpoint of OS was significantly longer with Sone-Ve than with investigator’s choice of therapy (IC; median 10 vs 5 months; hazard ratio [HR], 0.47; p<0.000001). The OS probability at 12 months was also markedly greater with Sone-Ve than IC (38.1 percent vs 18.1 percent).

“The OS HR point estimates favoured Sone-Ve over IC across all clinically relevant subgroups in the 3L+ population,” said Dr Rui-Hua Xu from Sun Yat-sen University, Guangzhou, China, at ESMO 2026.

Sone-Ve also showed a positive trend for the co-primary endpoint of progression-free survival (PFS) by blinded independent central review (BICR) in the intent-to-treat (ITT) population, but the difference did not meet the threshold for statistical significance (median 4.2 vs 3.8 months; HR, 0.77; p=0.053). [ESMO 2026, abstract LBA7]

Secondary endpoints

The OS benefit with Sone-Ve vs IC in the 3L+ cohort was consistent in the ITT population (median 10.6 vs 6.4 months; HR, 0.58; p<0.000004) and across CLDN18.2 expression subgroups (≥75 percent: median 10.6 vs 6.4 months; HR, 0.59; ≥25 to <75 percent: median 10.5 vs 6.2 months; HR, 0.63).

Sone-Ve also improved BICR-assessed PFS in the 3L+ population (median 4.1 vs 2.7 months; HR, 0.56) and investigator-assessed PFS in the ITT cohort (median 4.4 vs 3 months; HR, 0.59) compared with IC.

Sone-Ve outdid IC in terms of objective response rate (23.3 percent vs 13.8 percent), disease control rate (70.4 percent vs 55.6 percent), and median duration of response (8.5 vs 6.8 months).

Compared with the IC group, the Sone-Ve group had higher grade ≥3 gastrointestinal-related adverse event rates (decreased appetite: 9.6 percent vs 1.6 percent; nausea: 6.9 percent vs 2.8 percent; vomiting: 6.1 percent vs 2.8 percent) but lower haematologic event rates, including neutropenia (10.3 percent vs 25.4 percent), anaemia (8.4 percent vs 11.1 percent), and decreased neutrophil count (6.9 percent vs 18.7 percent).

A validated therapeutic target

CLDN18.2 is a tight junction protein expressed in 40–80 percent of GECs depending on the threshold for positivity used. [J Clin Oncol 2023;41(suppl 16):4035; Ann Oncol 2021;32:609-619]

Although CLDN18.2 has emerged as a validated therapeutic target, there are no CLDN18.2-targeted therapies approved for second or later-line (2L+) therapy, Xu said.

A total of 594 participants with 2L+ GEC expressing CLDN18.2 were randomized 1:1:1 to IV Sone-Ve 2.2 mg/kg Q3W, Sone-Ve 1.8 mg/kg Q3W, or IC. After closing the Sone-Ve 1.8-mg/kg group to enrolment (the higher Sone-Ve dose was determined to be the optimal monotherapy dose), 532 participants (median age 57 years, 58 percent men) were then randomized 1:1 to Sone-Ve 2.2 mg/kg Q3W or IC*.

A majority of the participants had tumours primarily located in the stomach (73.2–79.8 percent), had peritoneal metastasis (55.8–61 percent), had ≥75-percent CLDN18.2 expression (68.5–73.2 percent), and had >3 lines of therapy (66.3–66.8 percent).

“CLARITY-Gastric01 is the first global phase III trial to show a significant OS benefit and a manageable safety profile with a CLDN18.2-targeting ADC in patients with previously treated advanced or metastatic CLDN18.2-positive GEC … Sone-Ve is a potential new standard of care in the 2L+ setting for [this patient population],” Xu said.

“We are witnessing the next major step forward in the treatment of these patients, with the first phase III results on CLDN18.2-targeting ADCs as a new therapeutic standard, clearly improving the survival of these patients in an impressive way,” said discussant Dr Salah-Eddin Al-Batran from Krankenhaus Nordwest, Frankfurt, Germany.

 

*2L: Ramucirumab plus paclitaxel, paclitaxel, or docetaxel; 3L+: Irinotecan, trifluridine/tipiracil, or apatinib